LEQVIO is for LDL-C reduction in patients with primary hyperlipidemia along with diet and statin therapy.1
Navigate through the real-world experiences and uncover invaluable insights and answers to crucial questions specifically curated for you to gain a deeper understanding of what truly matters most.
For LDL-C reduction in patients with primary hyperlipidemia along with diet and statin therapy
EXPANDED INDICATION ENABLES BROADER USE OF LEQVIO
In July 2023, the FDA has approved the revised indication for use in patients with primary hyperlipidemia in addition to ESTABLISHED ASCVD and HeFH
Explore the MOA
View to learn more about how LEQVIO works differently than other LDL-C–lowering treatments as a complement to statins.
Dive Into siRNA Technology
View to learn more about LEQVIO—a small interfering RNA therapy that selectively targets the liver to regulate LDL-C levels.
How Do You Get Your Patients Started on LEQVIO?
Watch Dr Suzanne Shugg, Dr Rajkumar Sugumaran, and Dr Prediman K. Shah discuss the flexible pathways available for acquisition and administration of patients.
LEQVIO via Buy-and-Bill With In-Office Administration
Find out more about acquiring HCP-administered products like LEQVIO through buy-and-bill, the primary method for...
LEQVIO via Referral to an Alternate Injection Center (AIC)
If buy-and-bill is not your method of choice for acquiring LEQVIO, get details on how you can refer patients to an AIC to handle...
THERE'S MORE TO KNOW ABOUT LEQVIO
See how LEQVIO is there to support you and your patients